TY  - JOUR
AU  - Paz-Ares, L
AU  - Spira, A
AU  - Raben, D
AU  - Planchard, D
AU  - Cho, B C
AU  - Özgüroğlu, M
AU  - Daniel, D
AU  - Villegas, A
AU  - Vicente, D
AU  - Hui, R
AU  - Murakami, S
AU  - Spigel, D
AU  - Senan, S
AU  - Langer, C J
AU  - Perez, B A
AU  - Boothman, A-M
AU  - Broadhurst, H
AU  - Wadsworth, C
AU  - Dennis, P A
AU  - Antonia, S J
AU  - Faivre-Finn, C
PY  - 2020
DO  - 10.1016/j.annonc.2020.03.287
UR  - http://hdl.handle.net/10668/15280
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after...
LA  - en
KW  - PACIFIC
KW  - PD-L1 expression
KW  - durvalumab
KW  - immunotherapy
KW  - non-small-cell lung cancer
KW  - stage III
KW  - Antibodies, Monoclonal
KW  - B7-H1 Antigen
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Humans
KW  - Lung Neoplasms
TI  - Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
TY  - research article
VL  - 31
ER  -